Tvardi Therapeutics (TVRD) Stock: Buy, Sell, or Hold?
TVRD - Tvardi Therapeutics, Inc. Common Stock
$1.15
-0.09 (-7.26%)
▼
5d:
-9.45%
30d:
-38.83%
90d:
-42.79%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When TVRD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TVRD shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: TVRD shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: TVRD is currently trading at $1.15, which is considered oversold relative to its 30-day fair value range of $1.35 to $1.89.
Technical Outlook: Technically, TVRD is in a strong downtrend. Immediate support is located at $0.93, while resistance sits at $1.73. Short-term momentum is weak, with the stock down 7.3% recently.
Market Sentiment: TVRD scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $9.25 (+704.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TVRD is in a strong downtrend. Immediate support is located at $0.93, while resistance sits at $1.73. Short-term momentum is weak, with the stock down 7.3% recently.
Market Sentiment: TVRD scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $9.25 (+704.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.35 -
$1.89
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (63/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.3%)
- BULLISH: Trading 704.3% below Wall St target ($9.25)
- CAUTION: Bottoming setup, but lagging the sector by 52% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-9.4%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$1.35 -
$1.89
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.93
Resistance Level
$1.73
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.51
Wall Street Target
$9.25
(+704.3%)
Share & Embed Analysis
Last updated: October 04, 2026 1:38 AM ET
Data refreshes hourly during market hours. Next update: 2:38 AM
Data refreshes hourly during market hours. Next update: 2:38 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TVRD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 56 HOLD |